GlassScriptPhysician profile
Geoffrey G Correll
NPI 1861462426
$2,734.38
in general payments reported to CMS, 2019-2025
36 companies · $681 in 2025
The $681 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $63.95 · 2021: $222 · 2022: $410 · 2023: $473 · 2024: $534 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.88 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $282.69 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $205.07 | 2019-2025 | |
| Amgen INC. | $174.12 | 2019-2025 | Evenity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $173.88 | 2023-2025 | Lifevest |
| Idorsia Pharmaceuticals US INC | $166.94 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $127.62 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $125.24 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $124.49 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $113.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $92.62 | 2022 | |
| Medtronic, INC. | $73.09 | 2025 | Minimed 780g |
| Novo Nordisk INC | $65.52 | 2019-2023 | Wegovy |
| Axsome Therapeutics, INC. | $64.40 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.16 | 2019-2023 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $61.94 | 2019-2025 | Zoryve |
| Allergan, INC. | $49.54 | 2019-2020 | |
| Bausch Health US, LLC | $32.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.98 | 2019-2025 | |
| Antares Pharma, INC. | $29.52 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $28.02 | 2021 | |
| Corcept Therapeutics | $26.20 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $23.73 | 2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $23.13 | 2019-2021 | |
| Corium, LLC | $22.96 | 2024 | Azstarys |
| Astellas Pharma US INC | $19.86 | 2023 | Veozah |
| Philips North America LLC | $19.62 | 2024 | (Ck7) Extended Holter |
| Xeris Pharmaceuticals, INC. | $16.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.67 | 2019 | |
| Shield Therapeutics INC | $16.15 | 2023 | Accrufer |
| Clarus Therapeutics INC. | $15.93 | 2021 | |
| Dexcom, INC. | $14.59 | 2022 | |
| Eisai INC. | $13.55 | 2021 | |
| Tolmar, INC. | $13.51 | 2024 | |
| Amarin Pharma, INC. | $11.19 | 2021 | |
| Sanofi Pasteur INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Correll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.